Articles about 'drugs'

Many life-saving drugs directly interact with DNA to treat diseases such as cancer, but scientists have struggled to detect how and why they work – until now.

Adult and adolescent cannabis users are no more likely than non-users to lack motivation or be unable to enjoy life’s pleasure, new research has shown, suggesting there is no scientific basis for the stereotype often portrayed in the media.

While autistic individuals are less likely to use substances, those who do so are more likely to self-medicate for their mental health symptoms, according to new research from the University of Cambridge and published today in The Lancet Psychiatry.

Migrants arrested for tending plants in the flats, houses and attics where cannabis is grown in bulk are often victims of trafficking and 'debt bondage' – yet many are not recognised as such by police, according to a new study.

Scientists at AstraZeneca, a global biopharmaceutical company, have been working with Cambridge University for more than two decades. What are the secrets of their success?

Brexit could threaten the UK’s ability to tackle drug-related crime linked to serious and organised crime, according to public health experts writing today in the journal Health Policy.

Nanobots that patrol our bodies, killer immune cells hunting and destroying cancer cells, biological scissors that cut out defective genes: these are just some of technologies that Cambridge researchers are developing which are set to revolutionise medicine in the future.

Negative media coverage of the side effects associated with taking statins, and patients’ own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially life-saving drugs, according to research published today.

Tony Kouzarides is passionate about ecosystems: well-balanced communities that flourish on mutual and dynamic interactions. But the ecosystems that excite him are not made up of plants, animals and environments. They’re made up of experts.

When a drug fails late on in clinical trials it’s a major setback for launching new medicines. It can cost millions, even billions, of research and development funds. Now, an ‘adaptive’ approach to clinical trials and a genetic tool for predicting success are increasing the odds of picking a winner.